Timothy Creech, a long-time executive at Trimeris, is the new vice president of finance and chief accounting officer at Voyager Pharmaceutical.

Voyager is developing a treatment for Alzheimer’s disease and is pointing toward an initial public offering in 2005.

Creech earned a BS at the University of North Carolina at Chapel Hill and an MBA at Duke’s Fuqua School of Business. He worked at Trimeris for seven years, eventually serving as vice president of finance, principal accounting officer and secretary. He was actively involved in Trimeris’ IPO and the launch of its HIV drug Fuzeon.

Voyager: www.voyagerpharma.com